



Clinical trial results:

Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (Aducanumab) in Subjects With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

Summary

EudraCT number	2019-004368-22
Trial protocol	DE DK FI AT PL PT BE GB IT
Global end of trial date	22 July 2024

Results information

Result version number	v1 (current)
This version publication date	16 February 2025
First version publication date	16 February 2025

Trial information

Trial identification

Sponsor protocol code	221AD304
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04241068
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Biogen
Sponsor organisation address	225 Binney Street, Cambridge, United States, 02142
Public contact	Biogen Study Medical Director, Biogen, Biogen, clinicaltrials@biogen.com
Scientific contact	Biogen Study Medical Director, Biogen, Biogen, clinicaltrials@biogen.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	22 July 2024
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	22 July 2024
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

The primary objective is to evaluate the safety and tolerability of aducanumab over 100 weeks of treatment after a wash-out period imposed by discontinuation of feeder studies in participants who had previously received aducanumab (i.e. previously treated participants) or who had previously received placebo (i.e. treatment-naïve participants).

Protection of trial subjects:

Written informed consent was obtained from each participant or participant's legally authorized representative (e.g., legal guardian), as applicable, prior to evaluations performed for eligibility. Participants or the participant's legally authorized representative were given adequate time to review the information in the informed consent/assent and were allowed to ask, and have answered, questions concerning all portions of the conduct of the study.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	02 March 2020
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Austria: 5
Country: Number of subjects enrolled	Belgium: 34
Country: Number of subjects enrolled	Denmark: 11
Country: Number of subjects enrolled	Finland: 23
Country: Number of subjects enrolled	France: 61
Country: Number of subjects enrolled	Germany: 72
Country: Number of subjects enrolled	Italy: 92
Country: Number of subjects enrolled	Netherlands: 20
Country: Number of subjects enrolled	Poland: 83
Country: Number of subjects enrolled	Portugal: 20
Country: Number of subjects enrolled	Spain: 100
Country: Number of subjects enrolled	Sweden: 23
Country: Number of subjects enrolled	Australia: 52
Country: Number of subjects enrolled	Canada: 99
Country: Number of subjects enrolled	Japan: 130
Country: Number of subjects enrolled	Korea, Republic of: 33
Country: Number of subjects enrolled	Switzerland: 20

Country: Number of subjects enrolled	Taiwan: 8
Country: Number of subjects enrolled	United Kingdom: 33
Country: Number of subjects enrolled	United States: 777
Worldwide total number of subjects	1696
EEA total number of subjects	544

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	234
From 65 to 84 years	1401
85 years and over	61

Subject disposition

Recruitment

Recruitment details:

Participants took part in the study at the investigative sites in the United States, Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Japan, South Korea, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, Taiwan, and the United Kingdom from 02 Mar 2020 to 22 Jul 2024.

Pre-assignment

Screening details:

A total of 1696 participants were enrolled and treated in the core period, of which 1118 participants completed the core period. Out of the participants who completed the core period, 1041 participants entered the long-term extension (LTE) period, and 508 participants completed the LTE period.

Period 1

Period 1 title	Core Treatment Period
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Aducanumab
-----------	------------

Arm description:

Participants were administered aducanumab 10 milligrams per kilogram (mg/kg) by intravenous (IV) infusions every four weeks (Q4W) for 100 weeks during the Core Treatment Period. Eligible participants continued to receive aducanumab 10 mg/kg IV infusion, Q4W, for 52 weeks during the LTE Treatment Period.

Arm type	Experimental
Investigational medicinal product name	Aducanumab
Investigational medicinal product code	BIIB037
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous infusion, once every 4 weeks

Number of subjects in period 1	Aducanumab
Started	1696
Completed	1118
Not completed	578
Adverse event, serious fatal	26
Relocation	4
Reason Not Specified	41
Investigator Decision	40
Study Terminated by Sponsor	1
Study Visit Burden	40
Missing	2

Change of Treatment	4
Disease Progression	67
Consent Withdrawn	143
Loss of Capacity	9
Adverse event, non-fatal	91
Lost to follow-up	11
Withdrawal by Guardian/caretaker	99

Period 2

Period 2 title	LTE Period
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Aducanumab
------------------	------------

Arm description:

Participants were administered aducanumab 10 milligrams per kilogram (mg/kg) by intravenous (IV) infusions every four weeks (Q4W) for 100 weeks during the Core Treatment Period. Eligible participants continued to receive aducanumab 10 mg/kg IV infusion, Q4W, for 52 weeks during the LTE Treatment Period.

Arm type	Experimental
Investigational medicinal product name	Aducanumab
Investigational medicinal product code	BIIB037
Other name	
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Intravenous infusion, once every 4 weeks

Number of subjects in period 2	Aducanumab
Started	1041
Completed	508
Not completed	533
Adverse event, serious fatal	8
Relocation	6
Reason Not Specified	65
Investigator Decision	12
Site Terminated by Sponsor	26
Study Terminated by Sponsor	276

Study Visit Burden	10
Disease Progression	11
Change of Treatment	1
Consent Withdrawn	71
Loss of Capacity	2
Adverse event, non-fatal	19
Lost to follow-up	7
Withdrawal by Guardian/caretaker	19

Baseline characteristics

Subject analysis sets

Subject analysis set title	Aducanumab
Subject analysis set type	Full analysis

Subject analysis set description:

Participants were administered aducanumab 10 milligram per kilograms (mg/kg) by intravenous (IV) infusions every four weeks (Q4W) for 100 weeks during the Core Treatment Period. Eligible participants continued to receive aducanumab 10 mg/kg IV infusion, Q4W, for 52 weeks during the LTE Treatment Period.

Subject analysis set title	Aducanumab
Subject analysis set type	Full analysis

Subject analysis set description:

Participants were administered aducanumab 10 mg/kg by IV infusions, Q4W for 100 weeks during the Core Treatment Period.

Reporting group values	Aducanumab	Aducanumab	
Number of subjects	1696	1696	
Age Categorical			
Units: Subjects			

Age continuous			
Modified Intent-to-treat (mITT) population included all participants who had received at least one dose of aducanumab in the study 221AD304.			
Units: years			
arithmetic mean	73.1	0	
standard deviation	± 7.34	± 0	
Gender categorical			
Units: Subjects			
Male	815	0	
Female	881	0	
Race			
Units: Subjects			
Asian	185	0	
Black or African American	8	0	
White	1399	0	
Not Reported Due to Confidentiality Regulations	55	0	
Other	3	0	
Unknown	46	0	
Ethnicity			
Units: Subjects			
Hispanic or Latino	61	0	
Not Hispanic or Latino	1562	0	
Not Reported Due to Confidentiality Regulations	73	0	

End points

End points reporting groups

Reporting group title	Aducanumab
-----------------------	------------

Reporting group description:

Participants were administered aducanumab 10 milligrams per kilogram (mg/kg) by intravenous (IV) infusions every four weeks (Q4W) for 100 weeks during the Core Treatment Period. Eligible participants continued to receive aducanumab 10 mg/kg IV infusion, Q4W, for 52 weeks during the LTE Treatment Period.

Reporting group title	Aducanumab
-----------------------	------------

Reporting group description:

Participants were administered aducanumab 10 milligrams per kilogram (mg/kg) by intravenous (IV) infusions every four weeks (Q4W) for 100 weeks during the Core Treatment Period. Eligible participants continued to receive aducanumab 10 mg/kg IV infusion, Q4W, for 52 weeks during the LTE Treatment Period.

Subject analysis set title	Aducanumab
----------------------------	------------

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

Participants were administered aducanumab 10 milligram per kilograms (mg/kg) by intravenous (IV) infusions every four weeks (Q4W) for 100 weeks during the Core Treatment Period. Eligible participants continued to receive aducanumab 10 mg/kg IV infusion, Q4W, for 52 weeks during the LTE Treatment Period.

Subject analysis set title	Aducanumab
----------------------------	------------

Subject analysis set type	Full analysis
---------------------------	---------------

Subject analysis set description:

Participants were administered aducanumab 10 mg/kg by IV infusions, Q4W for 100 weeks during the Core Treatment Period.

Primary: Core Treatment Period: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

End point title	Core Treatment Period: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs ^[1]
-----------------	---

End point description:

AE=any untoward medical occurrence in participant/clinical investigation participant administered pharmaceutical product,that does not necessarily have causal relationship with this treatment.AE can be any unfavorable & unintended sign(including an abnormal laboratory finding),symptom/disease temporally associated with use of medicinal(investigational) product,whether or not related to medicinal(investigational)product. SAE=any untoward medical occurrence that at any dose results in death,is life-threatening event,requires inpatient hospitalization/prolongation of existing hospitalization,results in significant disability/incapacity/congenital anomaly,is medically important event.TEAE/Serious TEAEs=any AE that has onset date and time that is on/after date and time of first dose of study treatment/that has worsened after date and time of first dose of study treatment.Safety population for core period=all participants who had received atleast 1 dose of aducanumab in core

End point type	Primary
----------------	---------

End point timeframe:

From the first dose of study drug to end of follow-up (up to Week 118)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive statistics were planned for this endpoint.

End point values	Aducanumab			
Subject group type	Subject analysis set			
Number of subjects analysed	1696			
Units: participants				
TEAEs	1549			
Serious TEAEs	318			

Statistical analyses

No statistical analyses for this end point

Primary: Core Treatment Period: Number of Participants with AEs Leading to Treatment Discontinuation (TD) and Study Withdrawal (SW)

End point title	Core Treatment Period: Number of Participants with AEs Leading to Treatment Discontinuation (TD) and Study Withdrawal (SW) ^[2]
-----------------	---

End point description:

An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The safety population included all participants who had received at least one dose of aducanumab in the core period.

End point type	Primary
----------------	---------

End point timeframe:

From the first dose of study drug to end of follow-up (up to Week 118)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive statistics were planned for this endpoint.

End point values	Aducanumab			
Subject group type	Subject analysis set			
Number of subjects analysed	1696			
Units: participants				
AEs leading to TD	168			
AEs leading to SW	129			

Statistical analyses

No statistical analyses for this end point

Primary: Core Treatment Period: Number of Participants with Amyloid-Related Imaging Abnormality-Edema (ARIA-E)

End point title	Core Treatment Period: Number of Participants with Amyloid-Related Imaging Abnormality-Edema (ARIA-E) ^[3]
-----------------	--

End point description:

Number of participants diagnosed with ARIA edema are reported. The safety magnetic resonance imaging (MRI) population for the core period included all participants who had received at least one dose

of aducanumab in the core period and had at least one post-baseline MRI assessment in the core period. Here, 'overall number of participants analysed' signifies the number of participants with data available for outcome measure analysis.

End point type	Primary
End point timeframe:	
Up to Week 118	

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive statistics were planned for this endpoint.

End point values	Aducanumab			
Subject group type	Subject analysis set			
Number of subjects analysed	1656			
Units: participants	422			

Statistical analyses

No statistical analyses for this end point

Primary: Core Treatment Period: Number of Participants with Amyloid-Related Imaging Abnormality- Hemorrhage or Superficial Siderosis (ARIA-H)

End point title	Core Treatment Period: Number of Participants with Amyloid-Related Imaging Abnormality- Hemorrhage or Superficial Siderosis (ARIA-H) ^[4]
-----------------	---

End point description:

Number of participants diagnosed with ARIA hemorrhage or superficial siderosis are reported. The safety MRI population for the core period included all participants who had received at least one dose of aducanumab in the core period and had at least one post-baseline MRI assessment in the core period. Here, 'overall number of participants analysed' signifies the number of participants with data available for outcome measure analysis.

End point type	Primary
End point timeframe:	
Up to Week 118	

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive statistics were planned for this endpoint.

End point values	Aducanumab			
Subject group type	Subject analysis set			
Number of subjects analysed	1656			
Units: participants	505			

Statistical analyses

No statistical analyses for this end point

Primary: Core Treatment Period: Number of Participants With Positive Antidrug

Antibodies (ADAs) in Serum

End point title	Core Treatment Period: Number of Participants With Positive Antidrug Antibodies (ADAs) in Serum ^[5]
-----------------	--

End point description:

The presence of serum ADAs was determined using a validated assay. A standard 3-tiered approach was used including screening assay, confirmatory assay, and titration assay. The number of participants with a positive response to ADAs are reported. The immunogenicity population for the core period included all participants who had received at least one dose of aducanumab in the core period and had at least one post-dose sample evaluated for immunogenicity in the core period. Here, 'overall number of participants analysed' signifies the number of participants with data available for outcome measure analysis.

End point type	Primary
----------------	---------

End point timeframe:

Up to Week 102

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Only descriptive statistics were planned for this endpoint.

End point values	Aducanumab			
Subject group type	Subject analysis set			
Number of subjects analysed	1595			
Units: participants	19			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From first dose of study drug up to last follow-up visit (up to Week 170)

Adverse event reporting additional description:

The safety population included all participants who had received at least one dose of aducanumab in this study (221AD304).

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26.1
--------------------	------

Reporting groups

Reporting group title	Aducanumab
-----------------------	------------

Reporting group description:

Participants were administered aducanumab 10 mg/kg by IV infusions, Q4W for 100 weeks during the Core Treatment Period. Eligible participants continued to receive aducanumab 10 mg/kg IV infusion, Q4W, for 52 weeks during the LTE Treatment Period.

Serious adverse events	Aducanumab		
Total subjects affected by serious adverse events			
subjects affected / exposed	416 / 1696 (24.53%)		
number of deaths (all causes)	37		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma pancreas			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Atypical fibroxanthoma			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Basal cell carcinoma			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Benign nipple neoplasm			

subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Bladder cancer			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Bladder transitional cell carcinoma			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Breast cancer			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Endometrial cancer stage i			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Follicular lymphoma			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastric cancer			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastric cancer recurrent			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Glioblastoma			

subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Adenocarcinoma of colon			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Glioblastoma multiforme			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ovarian cancer			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Invasive ductal breast carcinoma			
subjects affected / exposed	3 / 1696 (0.18%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Invasive lobular breast carcinoma			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Invasive papillary breast carcinoma			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lung adenocarcinoma			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Lung adenocarcinoma stage iii			

subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lung cancer metastatic			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Lung neoplasm malignant			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lung squamous cell carcinoma stage iii			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Malignant melanoma			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Malignant peritoneal neoplasm			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Meningioma			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Metastatic bronchial carcinoma			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Metastatic uterine cancer			

subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Intraductal papillary mucinous neoplasm			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pancreatic carcinoma			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Prostate cancer			
subjects affected / exposed	5 / 1696 (0.29%)		
occurrences causally related to treatment / all	0 / 6		
deaths causally related to treatment / all	0 / 0		
Prostatic adenoma			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Squamous cell carcinoma of lung			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Squamous cell carcinoma of the tongue			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Uterine cancer			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Waldenstrom\'s macroglobulinaemia			

subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Hypertensive crisis			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Aortic stenosis			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Deep vein thrombosis			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hypertension			
subjects affected / exposed	3 / 1696 (0.18%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Hypotension			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Orthostatic hypotension			
subjects affected / exposed	3 / 1696 (0.18%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Internal haemorrhage			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
General disorders and administration site conditions			

Pyrexia				
subjects affected / exposed	1 / 1696 (0.06%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Asthenia				
subjects affected / exposed	2 / 1696 (0.12%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Chest pain				
subjects affected / exposed	1 / 1696 (0.06%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Death				
subjects affected / exposed	4 / 1696 (0.24%)			
occurrences causally related to treatment / all	0 / 4			
deaths causally related to treatment / all	0 / 4			
Gait disturbance				
subjects affected / exposed	1 / 1696 (0.06%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
General physical health deterioration				
subjects affected / exposed	2 / 1696 (0.12%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 1			
Malaise				
subjects affected / exposed	1 / 1696 (0.06%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Multiple organ dysfunction syndrome				
subjects affected / exposed	1 / 1696 (0.06%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Non-cardiac chest pain				

subjects affected / exposed	4 / 1696 (0.24%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Sudden death			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Systemic inflammatory response syndrome			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Anaphylactic reaction			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Anaphylactic shock			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Social circumstances			
Loss of personal independence in daily activities			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Benign prostatic hyperplasia			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Breast haematoma			

subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Breast swelling			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Colpocele			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Female genital tract fistula			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Prostatitis			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Choking			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Acute respiratory failure			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Atelectasis			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Chronic obstructive pulmonary disease			

subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Dyspnoea			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hypoxia			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Obstructive sleep apnoea syndrome			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Pulmonary embolism			
subjects affected / exposed	10 / 1696 (0.59%)		
occurrences causally related to treatment / all	0 / 10		
deaths causally related to treatment / all	0 / 1		
Pulmonary fibrosis			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory failure			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Aggression			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Agitation			

subjects affected / exposed	10 / 1696 (0.59%)		
occurrences causally related to treatment / all	0 / 11		
deaths causally related to treatment / all	0 / 0		
Behaviour disorder			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Confusional state			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Delirium			
subjects affected / exposed	3 / 1696 (0.18%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Disorientation			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Mental status changes			
subjects affected / exposed	7 / 1696 (0.41%)		
occurrences causally related to treatment / all	1 / 7		
deaths causally related to treatment / all	0 / 0		
Psychiatric decompensation			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Somatic symptom disorder			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Suicidal ideation			

subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Suicide attempt			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Tic			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Neuropsychological symptoms			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Investigations			
Colonoscopy			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Injury, poisoning and procedural complications			
Cervical vertebral fracture			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Accidental overdose			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Acetabulum fracture			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		

Ankle fracture				
subjects affected / exposed	1 / 1696 (0.06%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Arthropod sting				
subjects affected / exposed	1 / 1696 (0.06%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Cardiac valve replacement complication				
subjects affected / exposed	1 / 1696 (0.06%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Accident				
subjects affected / exposed	3 / 1696 (0.18%)			
occurrences causally related to treatment / all	0 / 3			
deaths causally related to treatment / all	0 / 0			
Concussion				
subjects affected / exposed	1 / 1696 (0.06%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Multiple fractures				
subjects affected / exposed	1 / 1696 (0.06%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Craniocerebral injury				
subjects affected / exposed	1 / 1696 (0.06%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Fall				
subjects affected / exposed	59 / 1696 (3.48%)			
occurrences causally related to treatment / all	1 / 62			
deaths causally related to treatment / all	0 / 1			
Femoral neck fracture				

subjects affected / exposed	14 / 1696 (0.83%)		
occurrences causally related to treatment / all	1 / 14		
deaths causally related to treatment / all	0 / 0		
Femur fracture			
subjects affected / exposed	6 / 1696 (0.35%)		
occurrences causally related to treatment / all	0 / 6		
deaths causally related to treatment / all	0 / 0		
Forearm fracture			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Foreign body in urogenital tract			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Fractured sacrum			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hand fracture			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Head injury			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Hip fracture			
subjects affected / exposed	7 / 1696 (0.41%)		
occurrences causally related to treatment / all	0 / 7		
deaths causally related to treatment / all	0 / 0		
Humerus fracture			

subjects affected / exposed	3 / 1696 (0.18%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Incisional hernia			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lumbar vertebral fracture			
subjects affected / exposed	3 / 1696 (0.18%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Contusion			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Patella fracture			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ulna fracture			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Post procedural haemorrhage			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Procedural pain			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Procedural pneumothorax			

subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Radius fracture			
subjects affected / exposed	3 / 1696 (0.18%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Rib fracture			
subjects affected / exposed	4 / 1696 (0.24%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Road traffic accident			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Spinal compression fracture			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Spinal fracture			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Subdural haematoma			
subjects affected / exposed	7 / 1696 (0.41%)		
occurrences causally related to treatment / all	0 / 7		
deaths causally related to treatment / all	0 / 0		
Subdural haemorrhage			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Thoracic vertebral fracture			

subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Tibia fracture			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Tooth injury			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Toxicity to various agents			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Traumatic intracranial haemorrhage			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pelvic fracture			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Urinary retention postoperative			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Wrong product administered			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Acute coronary syndrome			

subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Acute myocardial infarction			
subjects affected / exposed	4 / 1696 (0.24%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Atrial fibrillation			
subjects affected / exposed	13 / 1696 (0.77%)		
occurrences causally related to treatment / all	0 / 14		
deaths causally related to treatment / all	0 / 0		
Atrioventricular block			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Atrioventricular block complete			
subjects affected / exposed	5 / 1696 (0.29%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
Bradyarrhythmia			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Bradycardia			
subjects affected / exposed	3 / 1696 (0.18%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Cardiac arrest			
subjects affected / exposed	7 / 1696 (0.41%)		
occurrences causally related to treatment / all	0 / 7		
deaths causally related to treatment / all	0 / 7		
Cardiac failure			

subjects affected / exposed	4 / 1696 (0.24%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 1		
Cardiac failure chronic			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Atrioventricular block second degree			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cardiac failure congestive			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Cardio-respiratory arrest			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Coronary artery occlusion			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Stress cardiomyopathy			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Myocardial infarction			
subjects affected / exposed	4 / 1696 (0.24%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 2		
Pericarditis			

subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Sinus node dysfunction			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Left ventricular failure			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Supraventricular tachycardia			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ventricle rupture			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Ventricular extrasystoles			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ventricular tachycardia			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Tachycardia			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits			

subjects affected / exposed	3 / 1696 (0.18%)		
occurrences causally related to treatment / all	3 / 3		
deaths causally related to treatment / all	0 / 0		
Amyloid related imaging abnormality-oedema/effusion			
subjects affected / exposed	9 / 1696 (0.53%)		
occurrences causally related to treatment / all	8 / 9		
deaths causally related to treatment / all	0 / 0		
Autonomic nervous system imbalance			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Bell's palsy			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Carotid artery occlusion			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Carotid artery stenosis			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Cerebellar haematoma			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cerebellar stroke			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Idiopathic generalised epilepsy			

subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cerebral infarction			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cerebral ischaemia			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cerebrovascular accident			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	1 / 2		
deaths causally related to treatment / all	0 / 0		
Dementia alzheimer's type			
subjects affected / exposed	4 / 1696 (0.24%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Dementia of the alzheimer's type, with delirium			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Dementia with lewy bodies			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Dizziness			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Embolic stroke			

subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Encephalopathy			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Epilepsy			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Generalised tonic-clonic seizure			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Haemorrhagic cerebral infarction			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Haemorrhagic stroke			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cerebral haemorrhage			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Metabolic encephalopathy			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Mental impairment			

subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Presyncope			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Psychomotor hyperactivity			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Seizure			
subjects affected / exposed	13 / 1696 (0.77%)		
occurrences causally related to treatment / all	6 / 14		
deaths causally related to treatment / all	0 / 1		
Small fibre neuropathy			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Status epilepticus			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Subarachnoid haemorrhage			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Syncope			
subjects affected / exposed	23 / 1696 (1.36%)		
occurrences causally related to treatment / all	1 / 24		
deaths causally related to treatment / all	0 / 1		
Transient global amnesia			

subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Transient ischaemic attack			
subjects affected / exposed	8 / 1696 (0.47%)		
occurrences causally related to treatment / all	0 / 8		
deaths causally related to treatment / all	0 / 0		
Ischaemic cerebral infarction			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Ischaemic stroke			
subjects affected / exposed	9 / 1696 (0.53%)		
occurrences causally related to treatment / all	0 / 9		
deaths causally related to treatment / all	0 / 0		
Loss of consciousness			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Myelopathy			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Normocytic anaemia			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Anaemia vitamin b12 deficiency			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ear and labyrinth disorders			

Vertigo positional subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Cataract			
subjects affected / exposed	3 / 1696 (0.18%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
Retinal detachment			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Duodenal perforation			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Abdominal hernia			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Anorectal disorder			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Ascites			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Colitis			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

Colitis ischaemic				
subjects affected / exposed	2 / 1696 (0.12%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Constipation				
subjects affected / exposed	1 / 1696 (0.06%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Diverticulum intestinal haemorrhagic				
subjects affected / exposed	1 / 1696 (0.06%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Duodenal ulcer				
subjects affected / exposed	1 / 1696 (0.06%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Duodenal ulcer haemorrhage				
subjects affected / exposed	1 / 1696 (0.06%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Enteritis				
subjects affected / exposed	1 / 1696 (0.06%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Faecaloma				
subjects affected / exposed	1 / 1696 (0.06%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal disorder				
subjects affected / exposed	1 / 1696 (0.06%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal haemorrhage				

subjects affected / exposed	3 / 1696 (0.18%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Obstructive pancreatitis			
subjects affected / exposed	3 / 1696 (0.18%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Haemorrhoidal haemorrhage			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Inguinal hernia			
subjects affected / exposed	5 / 1696 (0.29%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
Intestinal ischaemia			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Intestinal obstruction			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Large intestine polyp			
subjects affected / exposed	3 / 1696 (0.18%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Leukoplakia oral			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrooesophageal reflux disease			

subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Oesophageal motility disorder			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Rectal prolapse			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Small intestinal obstruction			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Small intestinal perforation			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Umbilical hernia			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pancreatitis			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Bile duct stone			

subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Biliary colic			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cholecystitis			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cholecystitis acute			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cholelithiasis			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Angioedema			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Leukoplakia			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Chronic kidney disease			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Acute kidney injury			

subjects affected / exposed	4 / 1696 (0.24%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 1		
End stage renal disease			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hydronephrosis			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Nephrolithiasis			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Renal colic			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urinary retention			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Haematuria			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Osteoporotic fracture			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Arthralgia			

subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Back pain			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Chest wall haematoma			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Chondrocalcinosis			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Lumbar spinal stenosis			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Muscular weakness			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Osteoarthritis			
subjects affected / exposed	3 / 1696 (0.18%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Systemic lupus erythematosus			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Polymyalgia rheumatica			

subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Cat scratch disease			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Acute sinusitis			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Appendicitis			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Appendicitis perforated			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Bacterial infection			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Bronchitis			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cellulitis			
subjects affected / exposed	5 / 1696 (0.29%)		
occurrences causally related to treatment / all	0 / 5		
deaths causally related to treatment / all	0 / 0		
Lower respiratory tract infection			

subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Covid-19			
subjects affected / exposed	16 / 1696 (0.94%)		
occurrences causally related to treatment / all	0 / 16		
deaths causally related to treatment / all	0 / 3		
Covid-19 pneumonia			
subjects affected / exposed	8 / 1696 (0.47%)		
occurrences causally related to treatment / all	0 / 8		
deaths causally related to treatment / all	0 / 2		
Cystitis			
subjects affected / exposed	3 / 1696 (0.18%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 1		
Diverticulitis			
subjects affected / exposed	4 / 1696 (0.24%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 1		
Diverticulitis intestinal perforated			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Enterococcal sepsis			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Enterovirus infection			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Escherichia urinary tract infection			

subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Gingivitis			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Infective exacerbation of bronchiectasis			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Influenza			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Klebsiella urinary tract infection			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Clostridium difficile colitis			
subjects affected / exposed	4 / 1696 (0.24%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Meningitis			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	1 / 1		
deaths causally related to treatment / all	0 / 0		
Nasopharyngitis			

subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Neuroborreliosis			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Neutropenic sepsis			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Osteomyelitis			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Pneumonia			
subjects affected / exposed	10 / 1696 (0.59%)		
occurrences causally related to treatment / all	0 / 11		
deaths causally related to treatment / all	0 / 2		
Pneumonia aspiration			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Post procedural infection			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pyelonephritis			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Pyelonephritis acute			

subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Respiratory tract infection			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	3 / 1696 (0.18%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 2		
Septic shock			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Staphylococcal sepsis			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Streptococcal infection			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Subdural abscess			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Tracheobronchitis			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection			

subjects affected / exposed	4 / 1696 (0.24%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection pseudomonal			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Urosepsis			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 1		
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		
Dehydration			
subjects affected / exposed	4 / 1696 (0.24%)		
occurrences causally related to treatment / all	0 / 4		
deaths causally related to treatment / all	0 / 1		
Failure to thrive			
subjects affected / exposed	2 / 1696 (0.12%)		
occurrences causally related to treatment / all	0 / 2		
deaths causally related to treatment / all	0 / 0		
Hyponatraemia			
subjects affected / exposed	3 / 1696 (0.18%)		
occurrences causally related to treatment / all	0 / 3		
deaths causally related to treatment / all	0 / 0		
Hypovolaemia			
subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Malnutrition			

subjects affected / exposed	1 / 1696 (0.06%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 1		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Aducanumab		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1351 / 1696 (79.66%)		
Investigations			
Weight decreased			
subjects affected / exposed	91 / 1696 (5.37%)		
occurrences (all)	98		
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	355 / 1696 (20.93%)		
occurrences (all)	543		
Contusion			
subjects affected / exposed	92 / 1696 (5.42%)		
occurrences (all)	104		
Vascular disorders			
Hypertension			
subjects affected / exposed	130 / 1696 (7.67%)		
occurrences (all)	139		
Nervous system disorders			
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits			
subjects affected / exposed	443 / 1696 (26.12%)		
occurrences (all)	710		
Dizziness			
subjects affected / exposed	146 / 1696 (8.61%)		
occurrences (all)	189		
Amyloid related imaging abnormality-oedema/effusion			

subjects affected / exposed	424 / 1696 (25.00%)		
occurrences (all)	717		
Superficial siderosis of central nervous system			
subjects affected / exposed	232 / 1696 (13.68%)		
occurrences (all)	333		
Headache			
subjects affected / exposed	246 / 1696 (14.50%)		
occurrences (all)	441		
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	98 / 1696 (5.78%)		
occurrences (all)	115		
Gastrointestinal disorders			
Constipation			
subjects affected / exposed	87 / 1696 (5.13%)		
occurrences (all)	93		
Diarrhoea			
subjects affected / exposed	130 / 1696 (7.67%)		
occurrences (all)	170		
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	103 / 1696 (6.07%)		
occurrences (all)	121		
Psychiatric disorders			
Anxiety			
subjects affected / exposed	104 / 1696 (6.13%)		
occurrences (all)	116		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	140 / 1696 (8.25%)		
occurrences (all)	162		
Arthralgia			
subjects affected / exposed	158 / 1696 (9.32%)		
occurrences (all)	193		
Infections and infestations			

Covid-19			
subjects affected / exposed	427 / 1696 (25.18%)		
occurrences (all)	459		
Nasopharyngitis			
subjects affected / exposed	107 / 1696 (6.31%)		
occurrences (all)	130		
Urinary tract infection			
subjects affected / exposed	122 / 1696 (7.19%)		
occurrences (all)	181		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
26 August 2020	Safety data from the Phase 3 Studies 221AD301 and 221AD302 updated and with additional supporting information on the efficacy of aducanumab at 10 mg/kg dosing from the Phase 1b study, Study 221AD103.
07 March 2021	Text describing the rescreening criteria was revised.
18 January 2022	Added a 52-week LTE period (13 additional doses) to the ongoing study.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The study was terminated prematurely based on the sponsor's decision.

Notes: